Skip to main content
. 2022 Mar 9;81(5):653–661. doi: 10.1136/annrheumdis-2021-221865

Figure 1.

Figure 1

Trial design. Patients were randomised in a 3:2 ratio to mavrilimumab or placebo using disease type (new onset or relapsing/refractory) as a stratification factor. Prednisone was tapered over the 26-week study as specified in the protocol.